The G2019S mutation in LRRK2 imparts resiliency to kinase inhibition
Authors:
Open Access
- 1 November 2018
- journal article
- research article
- Published by Elsevier in Experimental Neurology
- Vol. 309, 1-13
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Neurological Disorders and Stroke
- Michael J. Fox Foundation for Parkinson's Research (15882)
This publication has 46 references indexed in Scilit:
- Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodiesBiochemical Journal, 2013
- Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutationsProceedings of the National Academy of Sciences, 2012
- Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathwayMolecular Neurodegeneration, 2012
- LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in miceHuman Molecular Genetics, 2011
- Regulation of LRRK2 Expression Points to a Functional Role in Human Monocyte MaturationPLOS ONE, 2011
- Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2Nature Chemical Biology, 2011
- Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's diseaseNature Medicine, 2010
- Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of α-synuclein, and apoptotic cell death in aged miceProceedings of the National Academy of Sciences, 2010
- Dependence of Leucine-rich Repeat Kinase 2 (LRRK2) Kinase Activity on DimerizationJournal of Biological Chemistry, 2009
- Dynamic and redundant regulation of LRRK2 and LRRK1 expressionBMC Neuroscience, 2007